| Trial Identifier: | D781WR00001 |
| Sponsor: | AstraZeneca |
| Start Date: | September 2025 |
| Primary Completion Date: | March 2028 |
| Study Completion Date: | March 2028 |
| Condition: | Anal Cancer; Bladder Cancer; Cervical Cancer; Endometrial Cancer; Esophageal cancer; Head and Neck Cancer; Liver Cancer; Skin Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Cancer - Other; Lung Cancer; Testicular Cancer; Thyroid Cancer |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
| Country | Location |
|---|---|
| USA, Alabama | Birmingham, Alabama, USA, 35223 |
| USA, Arizona | Casa Grande, Arizona, USA, 85122 |
| USA, California | San Diego, California, USA, 92123 |
| USA, Colorado | Aurora, Colorado, USA, 80045 |
| USA, Florida | Coral Springs, Florida, USA, 33065 |
| USA, Florida | Fort Myers, Florida, USA, 33901 |
| USA, Florida | Palm Harbour, Florida, USA, 34684 |
| USA, Illinois | O'Fallon, Illinois, USA, 62269 |
| USA, North Carolina | Durham, North Carolina, USA, 27705 |
| USA, North Carolina | Wilson, North Carolina, USA, 27893 |
| USA, Ohio | Canton, Ohio, USA, 44718 |
| USA, Ohio | Maumee, Ohio, USA, 43537 |
| USA, Pennsylvania | Philadelphia, Pennsylvania, USA, 19104 |
| USA, Tennessee | Chattanooga, Tennessee, USA, 37403 |
| USA, Texas | Dallas, Texas, USA, 75390 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2026 Pharma Intelligence UK Limited (Citeline), a Norstella company